Loading...
Market
What will be the primary source of BioNTech's revenue in the Q4 2024 earnings report?
2
Resolution / Starting Odds
Majority from COVID-19 vaccines • 25%
Majority from oncology projects • 25%
Majority from mRNA projects • 25%
Majority from other sources • 25%
BioNTech's Q4 2024 earnings report
Story
BioNTech Reports Significant Q2 Loss, Stock Slides 4%, Guidance Reiterated
Aug 5, 2024, 10:21 AM
BioNTech reported a significant quarterly loss in the second quarter of 2024, driven by a sharp decline in COVID-19 vaccine sales and increased investment in new product development. The company posted a net loss of €807.8 million, or €3.36 per share, compared to analysts' expectations of a €2.01 loss per share. Revenues for the quarter were €128.7 million, slightly below the estimated €131.64 million. BioNTech invested €525.6 million, approximately 90% of its total R&D spend, in non-COVID-19 related activities, primarily oncology and mRNA projects. This strategic shift towards cancer treatments comes as the company faces reduced demand for its COVID-19 vaccines. BioNTech's stock slid 4% after the earnings report, and the company reiterated its full-year guidance.
View original story
Similar markets
COVID-19 vaccines • 25%
RSV vaccines • 25%
Other vaccines • 25%
Non-vaccine products • 25%
Moderna • 25%
Pfizer/BioNTech • 25%
Novavax • 25%
Other • 25%
Paxlovid • 25%
Comirnaty • 25%
Prevnar • 25%
Other • 25%
COVID-19 Vaccine • 25%
RSV Vaccine • 25%
Other Products • 25%
No clear top-seller • 25%
Below $100 • 25%
$100 - $150 • 25%
$150 - $200 • 25%
Above $200 • 25%
Less than $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
More than $12 billion • 25%
COVID-19 Vaccine • 25%
RSV Vaccine • 25%
Other Vaccines • 25%
Equal Contribution • 25%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
Pfizer exceeds expectations • 25%
Moderna exceeds expectations • 25%
Both exceed expectations • 25%
Neither exceed expectations • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%